Agios Pharmaceuticals (AGIO) Current Deferred Revenue (2012 - 2022)

Agios Pharmaceuticals has reported Current Deferred Revenue for 10 years, with the latest figure at $2.5 million in Q1 2022.

• For the quarter ending Q1 2022, Current Deferred Revenue changed N/A year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2022 stood at $2.5 million (changed N/A YoY), and the FY2019 full-year result was $10.9 million, down 66.58% from the prior year.
• Current Deferred Revenue for Q1 2022 stood at $2.5 million, up from $306000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $41.1 million in Q2 2018, with the low at $306000.0 in Q1 2020.
• Historically, Current Deferred Revenue has averaged $18.0 million across 4 years, with a median of $13.9 million in 2019.
• Annual changes were most pronounced in 2018 — Current Deferred Revenue tumbled 98.09% — and 2019, when it jumped 2359.62%.
• Agios Pharmaceuticals' Current Deferred Revenue stood at $32.7 million in 2018, then sank by 66.58% to $10.9 million in 2019, then slumped by 97.2% to $306000.0 in 2020, then soared by 716.99% to $2.5 million in 2022.
• The last three Current Deferred Revenue figures came in at $2.5 million (Q1 2022), $306000.0 (Q1 2020), and $10.9 million (Q4 2019), per Business Quant data.